alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 12.2**

 

**CERTIFICATION**

 

I, Johnny Cheng, certify that:

 

1. I have reviewed this Amendment No.1 to the annual report (the “**Report**”) on Form 20-F of Hutchison China MediTech Limited (the “**Company**”); and

 

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report.

 

Date: May 2, 2019

 
| By:    | /s/ Johnny Cheng        |   |
|--------|-------------------------|--------|
| Name:  | Johnny Cheng            |   |
| Title: | Chief Financial Officer |   |

 

----
§ 556.650 Sulfaethoxypyridazine. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for sulfaethoxypyridazine are: ( 1 ) *Cattle.* ( i ) Edible tissues (excluding milk): 0.1 ppm.
( ii ) Milk: Zero.
( 2 ) *Swine.* Edible tissues: Zero.
( c ) *Related conditions of use.* See §§ 520.2240a, 520.2240b, and 522.2240 of this chapter.
NOTE: This disposition is nonprecedential. 

United States Court of Appeals 

for the Federal Circuit ______________________ 

ADVANCE CONSTRUCTION SERVICES, INC., 

Appellant, 

v. 

JOHN MCHUGH, SECRETARY OF THE ARMY, 

Appellee. 

____________________ 

2011-1536 

______________________

 

 Appeal from the Armed Services Board of Contract 

Appeals in Case No. 55232, Administrative Judge Owen 

C. Wilson. 

______________________ 

JUDGMENT 

______________________ 

G. SCOTT WALTERS, Smith Currie & Hancock, LLP, of 

Atlanta, Georgia, argued for appellant. With him on the 

brief was HUBERT J. BELL, JR. 

BRYANT G. SNEE, Deputy Director, Commercial 

Litigation Branch, Civil Divison, United States 

Department of Justice, of Washington, DC, argued for 

appellee. With him on the brief were TONY WEST, 

Assistant Attorney General, JEANNE E. DAVIDSON, 

Director, and DAWN E. GOODMAN, Trial Attorney. 

______________________ 
THIS CAUSE having been heard and considered, it is 

ORDERED and ADJUDGED: 

 PER CURIAM (BRYSON, PROST, and REYNA, Circuit 

Judges). 

AFFIRMED. See Fed. Cir. R. 36. 

 ENTERED BY ORDER OF THE COURT

 July 12, 2012 /s/ Jan Horbaly

 Date Jan Horbaly 

 Clerk
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
     QUARTERLY REPORT 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
     FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                           0000813807
<NAME>                          COURTYARD BY MARRIOTT LIMITED PARTNERSHIP
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. DOLLAR

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   JUN-16-2000
<EXCHANGE-RATE>                                1.00
<CASH>                                         15,634
<SECURITIES>                                   0
<RECEIVABLES>                                  5,589
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               23,476
<PP&E>                                         511,706
<DEPRECIATION>                                 (227,072)
<TOTAL-ASSETS>                                 329,333
<CURRENT-LIABILITIES>                          25,860
<BONDS>                                        315,937
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     (12,464)
<TOTAL-LIABILITY-AND-EQUITY>                   329,333
<SALES>                                        0
<TOTAL-REVENUES>                               99,719
<CGS>                                          0
<TOTAL-COSTS>                                  0
<OTHER-EXPENSES>                               77,877
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             11,627
<INCOME-PRETAX>                                10,215
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            0
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   10,215
<EPS-BASIC>                                    0
<EPS-DILUTED>                                  0




</TABLE>
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Marilyn Kelly

Stephen J. Markman

Diane M. Hathaway

Mary Beth Kelly

Brian K. Zahra, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 _________________________________________

 Clerk

July 24, 2012

t0716

Order 

July 24, 2012

144949

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 144949

COA: 299151 

Muskegon CC: 09-058530-FC

DENNIS LONNIE-ALFRED WARD,

Defendant-Appellant. 

_________________________________________/

On order of the Court, the application for leave to appeal the January 24, 2012 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsFunding and Strategic Alignment Guidance for Infusing Small Business Innovation Research Technology into Aeronautics Research Mission Directorate Projects for 2016This report is intended to help NASA program and project managers incorporate Small Business Innovation Research (SBIR) technologies into NASA Aeronautics Research Mission Directorate (ARMD) projects. Other Government and commercial project managers interested in ARMD funding opportunities through NASA's SBIR program will find this report useful as well.Document ID20170002626Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsNguyen, Hung D.*(NASA Glenn Research Center Cleveland, OH United States)*Steele, Gynelle C.*(NASA Glenn Research Center Cleveland, OH United States)*Date AcquiredMarch 29, 2017Publication DateMarch 1, 2017Subject CategoryAdministration And ManagementAeronautics (General)Report/Patent NumberNASA/TM-2017-219458E-19283GRC-E-DAA-TN35401Funding Number(s)WBS: WBS 471296.01.03.01Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.KeywordsStructural Efficiency; Aeroelasticity; Low Emissions; Combustion Technology; AerAvailable DownloadsNameType20170002626.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
<PAGE>   1



                                                                    Exhibit 24.4

                       POWER OF ATTORNEY OF DANIEL B. WARD


     KNOW ALL MEN BY THESE PRESENTS, that the undersigned, Daniel B. Ward,
hereby constitutes and appoints William D. St. John or Steven H. Moger his true
and lawful attorney-in-fact and agent, for him and his name, place and stead, in
any and all capacities, to sign the Registration Statement on Form S-8,
registering 2,982,000 shares of common stock of Nutraceutix, Inc., a Delaware
corporation, issuable upon exercise of options granted pursuant to the
Nutraceutix, Inc. 1995 Amended Stock Option Plan, and any amendments (including
post-effective amendments) or supplements thereto, and to file this Power of
Attorney and the Form S-8, with all exhibits thereto, and other documents in
connection therewith with the Securities and Exchange Commission and any stock
exchange or similar authority, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing
requisite or necessary to be done in and about the premises, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorney-in-fact and agent may do or cause to be done
by virtue hereof.

     This Power of Attorney shall remain in full force and effect until revoked
by the undersigned in a signed writing delivered to the foregoing
attorney-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 25th day of May, 1999.



                                   /s/       Daniel B. Ward
                                   ---------------------------------------------
                                   DANIEL B. WARD
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5150 Bence-Jones proteins immunological test system. ( a ) *Identification.* A Bence-Jones proteins immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the Bence-Jones proteins in urine and plasma. Immunoglobulin molecules normally consist of pairs of polypeptide chains (subunits) of unequal size (light chains and heavy chains) bound together by several disulfide bridges. In some cancerous conditions, there is a proliferation of one plasma cell (antibody-producing cell) with excess production of light chains of one specific kind (monoclonal light chains). These free homogeneous light chains not associated with an immunoglobulin molecule can be found in urine and plasma, and have been called Bence-Jones proteins. Measurement of Bence-Jones proteins and determination that they are monoclonal aid in the diagnosis of multiple myeloma (malignant proliferation of plasma cells), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins by spleen and bone marrow cells), leukemia (cancer of the blood-forming organs), and lymphoma (cancer of the lymphoid tissue).
( b ) *Classification.* Class II (performance standards).
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7854 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7854

 To require schools and child welfare agencies to be notified when an 
 unaccompanied minor is placed in the jurisdiction of such schools and 
                               agencies.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 2, 2024

 Mr. Griffith introduced the following bill; which was referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
 To require schools and child welfare agencies to be notified when an 
 unaccompanied minor is placed in the jurisdiction of such schools and 
                               agencies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Unaccompanied Minor Placement 
Notification Act''.

SEC. 2. RESPONSIBILITY OF DIRECTOR TO NOTIFY LOCAL SCHOOLS AND CHILD 
              WELFARE AGENCIES OF PLACEMENT.

    Section 462(b)(2) of the Homeland Security Act of 2002 (6 U.S.C. 
Sec.  279(b)(2)) is amended--
            (1) in subparagraph (A)(iii), by striking ``and'' at the 
        end;
            (2) in subparagraph (B), by striking the period and 
        inserting ``; and''; and
            (3) by adding at the end the following:
                    ``(C) shall, not later than 96 hours after a 
                placement determination releasing an unaccompanied 
                alien child to a qualified sponsor, notify the school 
                district and child welfare agency in the jurisdiction 
                where an unaccompanied alien child is to be placed of 
                the placement, including the address of the sponsor's 
                residence, to ensure the child's welfare and continuity 
                of education.''.
                                 <all>
```
Exhibit 31.2
 Certification
  1.
    
    I have reviewed this annual report on Form 10-K of AXS-One Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.
    
    The registrants other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
     5.
    
    The registrants other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of the registrants board of directors (or persons performing the equivalent
functions):
   Date:  April 30, 2009
    /s/ Joseph P. DwyerJoseph P. DwyerExecutive Vice President, Chief Financial Officer,
and Treasurer
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.5050 Surgical smoke precipitator. ( a ) *Identification.* A surgical smoke precipitator is a prescription device intended for clearance of the visual field by precipitation of surgical smoke and other aerosolized particulate matter created during laparoscopic surgery.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Adverse tissue reaction must be mitigated through the following: ( i ) Chemical characterization and toxicological risk assessment of the treated surgical smoke.
( ii ) Demonstration that the elements of the device that may contact the patient are biocompatible.
( 2 ) Electrical safety and electromagnetic compatibility testing must demonstrate that the device performs as intended.
( 3 ) Software verification, validation, and hazard analysis must be performed.
( 4 ) Performance data must demonstrate the sterility of the patient contacting components of the device.
( 5 ) Performance data must support the shelf life of the sterile components of the device by demonstrating continued functionality, sterility, and package integrity over the identified shelf life.
( 6 ) Animal simulated-use testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Device must be demonstrated to be effectively inserted, positioned, and removed from the site of use.
( ii ) Device must be demonstrated to precipitate surgical smoke particulates to clear the visual field for laparoscopic surgeries.
( iii ) Device must be demonstrated to be non-damaging to the site of use and animal subject.
( 7 ) Labeling must identify the following: ( i ) Detailed instructions for use.
( ii ) Electrical safety and electromagnetic compatibility information.
( iii ) A shelf life.
[83 FR 4143, Jan. 30, 2018]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5340 Ferritin immunological test system. ( a ) *Identification.* A ferritin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the ferritin (an iron-storing protein) in serum and other body fluids. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency amemia.
( b ) *Classification.* Class II (performance standards).
s 

Terri Zick to: Christopher Lambesis 

Cc: Jake Gadd 

From: Terri Zick <tzick©cticompanies.com > 

To: Christopher Lambesis/R5/USEPA/US@EPA 

Cc: Jake Gadd <jakegadd©owossographic.com > 

06/08/2009 01:55 PM 

••,••••,-•••• ■ •-•••••••,•,,•, 

ChristopherAs a follow up to the voice mail message that I left you last week, I would like to discuss the status of the 

Owosso Graphic Arts petition. You had indicated in a previous phone message to me that there are some 

issues involving the change in developer process that you would like to discuss. 

As described in our March 31, 2009 correspondence (attached), the process change provides superior 

segregation of the development process from the etching process than was achieved with the aqueous 

developer (and TCE before that). As described in the attached letter, the developer is rinsed from the 

plate, and the plate heated over an open flame prior to entering the etching process. The two parts of the 

process are now effectively isolated from one another, which should further limit the chance of any of the 

developer being contributed to the filter cake. 

Please give me a call or e-mail at your next available time so that we may resolve this remaining issue. 

Thank you 

Terri Zick 

313-300-7401 cell 

248-486-5090 x232 office 

tzick@cticompanies.com 

The information contained in this electronic message is privileged and/or confidential information intended only for the use of the 

individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible 

to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of the communication is 

neither allowed nor intended. If you have received this commutzick@cticompanies.comase immediately notify us by return e-mail or by 

calling 8jakegadd@owossographic.come message. Thank You!
# C_2017357EN.01000802.xml

| 23.10.2017 | EN | Official Journal of the European Union | C 357/8 |
| --- | --- | --- | --- |

23.10.2017

EN

Official Journal of the European Union

C 357/8

---

Judgment of the General Court of 12 September 2017 — Bayerische Motoren Werke v Commission

(Case T-671/14) (1)

1

((State aid - Regional investment aid - Aid granted by Germany to BMW for a large investment project in Leipzig concerning the production of two models of electric cars (i3 and i8) - Decision declaring the aid partly compatible and partly incompatible with the internal market - Article 107(3)(c) TFEU - Article 108(2) and (3) TFEU - Incentive effect of the aid - Whether the aid is necessary))

(2017/C 357/10)

Language of the case: German

Parties

Parties

Applicant: Bayerische Motoren Werke AG (Munich, Germany) (represented by: M. Rosenthal, G. Drauz and M. Schütte, lawyers)

Applicant:

Defendant: European Commission (represented: initially by F. Erlbacher, T. Maxian Rusche and R. Sauer, and subsequently by T. Maxian Rusche and R. Sauer, acting as Agents)

Defendant:

Intervener in support of the applicant: Freistaat Sachsen (Germany) (represented by: T. Lübbig and K. Gaßner, lawyers)

Intervener in support of the applicant:

Re:

Re:

Application pursuant to Article 263 TFEU for partial annulment of Commission Decision C(2014) 4531 final of 9 July 2014 on the State aid No SA.32009 (2011/C) (ex 2010/N) which the Federal Republic of Germany plans to grant to BMW for a large investment project in Leipzig.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Bayerische Motoren Werke AG to bear its own costs and to pay those incurred by the European Commission; |
| --- | --- |

2.

Orders Bayerische Motoren Werke AG to bear its own costs and to pay those incurred by the European Commission;

| 3. | Orders the Freistaat Sachsen to bear its own costs. |
| --- | --- |

3.

Orders the Freistaat Sachsen to bear its own costs.

---

(1)  OJ C 439, 8.12.2014.

1

---
I 

118TH CONGRESS 

2D SESSION H. R. 7689 

To amend title 18, United State Code, to amend the definition of ‘‘official 

act’’ for purposes of the prohibition of bribery. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 15, 2024 

Ms. CRAIG (for herself, Ms. MACE, Mr. SORENSEN, and Mr. KIM of New Jersey) introduced the following bill; which was referred to the Committee 

on the Judiciary 

A BILL 

To amend title 18, United State Code, to amend the definition of ‘‘official act’’ for purposes of the prohibition 

of bribery. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Gifts for Officials, Leg5 islators and Delegate (GOLD) Standard Act of 2024’’. 

6 SEC. 2. OFFICIAL ACT DEFINED. 

7 Section 201(a) of title 18, United States Code, is 

8 amended by striking paragraph (3) and inserting the fol9 lowing: 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7689 IH

1 ‘‘(3) the term ‘official act’ means any decision, 

2 action, approval, disapproval, recommendation, ren3 dering of advice, or investigation on any question, 

4 matter, cause, suit, proceeding or controversy, which 

5 may at any time be pending, or which may by law 

6 be brought before any public official, in such offi7 cial’s official capacity, or in such official’s place of 

8 trust or profit.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
# C_2015414EN.01002902.xml

| 14.12.2015 | EN | Official Journal of the European Union | C 414/29 |
| --- | --- | --- | --- |

14.12.2015

EN

Official Journal of the European Union

C 414/29

---

Judgment of the General Court of 23 October 2015 — Hansen v OHIM (WIN365)

(Case T-264/14) (1)

1

((Community trade mark - Application for Community word mark WIN365 - Absolute ground for refusal - Lack of distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2015/C 414/38)

Language of the case: German

Parties

Parties

Applicant: Robert Hansen (Munich, Germany) (represented by: M. Pütz-Poulalion, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 20 February 2014 (Case R 908/2013-4), concerning an application for registration of the word sign WIN365 as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Mr Robert Hansen to pay the costs. |
| --- | --- |

2.

Orders Mr Robert Hansen to pay the costs.

---

(1)  OJ C 194, 24.6.2014.

1

---